Valacyclovir in the treatment of acute retinal necrosis
To report the outcome of oral valacyclovir as the sole antiviral therapy for patients with acute retinal necrosis (ARN).
This study reports a retrospective, interventional case series of nine consecutive patients with ten eyes with newly diagnosed ARN treated with oral valacyclovir as the sole antiviral agent. Eight patients received oral valacyclovir 2 g tid (Valtrex, GlaxoSmithKline) and one patient with impaired renal function received oral 1 g tid. The main outcome measures were response to treatment, time to initial response to treatment, time to complete resolution of retinitis, best corrected visual acuity (BCVA) at final follow-up, retinal detachment and development of recurrent or second eye disease.
Retinitis resolved in ten of ten (100%) affected eyes. The median time to initial detectable response was seven days and the median time to complete resolution was 21 days. A final BCVA of 20/40 or better was achieved in 6/10 (60%) of eyes. 3/10 eyes (30%) developed a retinal detachment. No patients developed either disease reactivation or second eye involvement over the course of the study (mean follow up 31 weeks, range 7 to 104 weeks).
Treatment with oral valacyclovir as the sole antiviral therapy resulted in complete resolution of retinitis. Final BCVA and retinal detachment rate were comparable with previously reported outcomes for intravenous acyclovir.
- Urayama A, Yamada M, Susaki T: Unilateral acute uveitis with periarteritis and detachment [in Japanese]. Rinsho Ganka 1971, 25:607–619.
- Blumenkranz MS, Culbertson WW, Clarkson JG, Dix R: Treatment of the acute retinal necrosis syndrome with intravenous acyclovir. Ophthalmology 1986,93(3):296–300.
- Culbertson WW, Blumenkranz MS, Haines H, Gass DM, Mitchell KB, Norton EW: The acute retinal necrosis syndrome. part 2: histopathology and etiology. Ophthalmology 1982,89(12):1317–1325.
- Nussenblatt R, Whitcup S: Uveitis :Fundamentals and clinical practice. 3rd edition. Philadelphia: Mosby; 2004.
- Aizman A, Johnson MW, Elner SG: Treatment of acute retinal necrosis syndrome with oral antiviral medications. Ophthalmology 2007,114(2):307–312. CrossRef
- Aslanides IM, De Souza S, Wong DTW, Giavedoni LR, Altomare F, Detorakis ET, Kymionis GD, Pallikaris IG: Oral valacyclovir in the treatment of acute retinal necrosis syndrome. Retina 2002,22(3):352–354. CrossRef
- Emerson GG, Smith JR, Wilson DJ, Rosenbaum JT, Flaxel CJ: Primary treatment of acute retinal necrosis with oral antiviral therapy. Ophthalmology 2006,113(12):2259–2261. CrossRef
- Figueroa MS, Garabito I, Gutierrez C, Fortun J: Famciclovir for the treatment of acute retinal necrosis (ARN) syndrome. Am J Ophthalmol 1997,123(2):255–257.
- Guex-Crosier Y, Meylan PR: High dosage of oral valaciclovir as an alternative treatment of varicella zoster acute retinal necrosis syndrome. Eye 2006,20(2):247. CrossRef
- Savant V, Saeed T, Denniston A, Murray PI: Oral valganciclovir treatment of varicella zoster virus acute retinal necrosis. Eye 2004,18(5):544–545. CrossRef
- Hillenkamp J, Elle B, Bruns C, Rautenberg P, Fickenscher H, Roider J: Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology 2009,116(10):1971–1975. e1972 CrossRef
- Kawaguchi T, Spencer DB, Mochizuki M: Therapy for acute retinal necrosis. Semin Ophthalmol 2008,23(4):285–290. CrossRef
- Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J: Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother 1995,39(12):2759–2764. CrossRef
- Tibbetts MD, Shah CP, Young LH, Duker JS, Maguire JI, Morley MG: Treatment of acute retinal necrosis. Ophthalmology 2010,117(4):818–824. CrossRef
- Holland GN: Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive Committee of the American Uveitis Society. Am J Ophthalmol 1994,117(5):663–667.
- Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ: A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV retinopathy. study group. Arch Ophthalmol 1989,107(12):1759–1766. CrossRef
- Crapotta JA, Freeman WR, Feldman RM, Lowder CY, Ambler JS, Parker CE, Meisler DM: Visual outcome in acute retinal necrosis. Retina 1993,13(3):208–213. CrossRef
- Lau CH, Missotten T, Salzmann J, Lightman SL: Acute retinal necrosis features, management, and outcomes. Ophthalmology 2007,114(4):756–762. CrossRef
- Sims JL, Yeoh J, Stawell RJ: Acute retinal necrosis: a case series with clinical features and treatment outcomes. Clin Experiment Ophthalmol 2009,37(5):473–477. CrossRef
- Wong R, Pavesio CE, Laidlaw DAH, Williamson TH, Graham EM, Stanford MR: Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. Ophthalmology 2010,117(3):556–560. CrossRef
- Palay DA, Sternberg P Jr, Davis J, Lewis H, Holland GN, Mieler WF, Jabs DA, Drews C: Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. J Ophthalmol 1991,112(3):250–255.
- Meghpara B, Sulkowski G, Kesen MR, Tessler HH, Goldstein DA: Long-term follow-up of acute retinal necrosis. Retina 2010,30(5):795–800. CrossRef
- de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, Zierhut M, Barisani-Asenbauer T, LeHoang P, Lightman S: Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011,30(6):452–470. CrossRef
- Ezra E, Pearson RV, Etchells DE, Gregor ZJ: Delayed fellow eye involvement in acute retinal necrosis syndrome. Am J Ophthalmol 1995,120(1):115–117.
- Falcone PM, Brockhurst RJ: Delayed onset of bilateral acute retinal necrosis syndrome: a 34-year interval. Ann Ophthalmol 1993,25(10):373–374.
- Carney MD, Peyman GA, Goldberg MF, Packo K, Pulido J, Nicholson D: Acute retinal necrosis. Retina 1986,6(2):85–94. CrossRef
- Beutner KR: Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995,28(4):281–290. CrossRef
- Lycke J, Malmestrom C, Stahle L: Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother 2003,47(8):2438–2441. CrossRef
- O’Brien JJ, Campoli-Richards DM: Acyclovir. an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989,37(3):233–309. CrossRef
- Chong DY, Johnson MW, Huynh TH, Hall EF, Comer GM, Fish DN: Vitreous penetration of orally administered famciclovir. Am J Ophthalmol 2009,148(1):38–42. e31 CrossRef
- Hoglund M, Ljungman P, Weller S: Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001,47(6):855–861. CrossRef
- Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, Smiley ML: Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther 1993,54(6):595–605. CrossRef
- Perry CM, Faulds D: Valaciclovir. a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 1996,52(5):754–772. CrossRef
- Bell WR, Chulay JD, Feinberg JE: Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997,76(5):369–380. CrossRef
- Vigil KJ, Chemaly RF: Valacyclovir: approved and off-label uses for the treatment of herpes virus infections in immunocompetent and immunocompromised adults. Expert Opin Pharmacother 2010,11(11):1901–1913. CrossRef
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2415/12/48/prepub
- Valacyclovir in the treatment of acute retinal necrosis
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- September 2012
- Online ISSN
- BioMed Central
- Additional Links
- Acute retinal necrosis
- Herpetic retinitis
- Author Affiliations
- 1. Division of Immunology & Inflammation, Faculty of Medicine, Imperial College London, London, UK
- 2. Royal Surrey County Hospital NHS Foundation Trust, Guildford, UK
- 3. Moorfields Eye Hospital, London, UK
- 4. UCL Institute of Ophthalmology, London, UK